0.5348  0.027 (5.34%)		09-16 12:04
Open: 0.535 High: 0.5402 Volume: 61,780		Pre. Close: 0.5077 Low: 0.511 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	1.01	1-year :	1.27
Resists	First :	0.86	Second :	1.09
Pivot price	0.59
Supports	First :	0.5	Second :	0.41
MAs	MA(5) :	0.54	MA(20) :	0.65
	MA(100) :	1.96	MA(250) :	44.52
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	4.1	D(3) :	6.7
RSI	RSI(14): 32.4
52-week	High :	993.95	Low :	0.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KALA ] has closed above bottom band by 33.1%. Bollinger Bands are 81.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.55 - 0.56	0.56 - 0.56
Low:	0.49 - 0.5	0.5 - 0.5
Close:	0.5 - 0.51	0.51 - 0.51

Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.

Tue, 15 Sep 2026
Kala Bio and Virotek partner on US ophthalmic genetic testing - Glance by Eyes On Eyecare

Thu, 10 Sep 2026
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com

Thu, 10 Sep 2026
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - TradingView

Thu, 10 Sep 2026
KALA BIO, Inc. Enters Exclusive Distribution And Reseller Agreement With Virotek, Inc - marketscreener.com

Wed, 09 Sep 2026
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan

Thu, 03 Sep 2026
Kala Bio and Virotek Finalize Definitive Agreement - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	19 (M)
Shares Float	19 (M)
Held by Insiders	1.2 (%)
Held by Institutions	3.6 (%)
Shares Short	255 (K)
Shares Short P.Month	257 (K)

EPS	-9.4
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.46
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-65.5 %
Return on Equity (ttm)	-345.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.25
Qtrly Earnings Growth	0 %
Operating Cash Flow	-20 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-0.06
PEG Ratio	0
Price to Book value	1.12
Price to Sales	0
Price to Cash Flow	-0.52

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.